OncLive SOSS

Authors

Mark Emberton, MD

Latest:

Dr. Emberton on Focal Therapy Techniques in Prostate Cancer

Mark Emberton, MD, professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London Hospitals, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses techniques of focal therapy in patients with prostate cancer.

Mark Emberton, MD, FRCS

Latest:

Dr. Emberton on the Importance of Multidisciplinary Care in Prostate Cancer

Mark Emberton, MD, FRCS, professor, Interventional Oncology, Division of Surgery and Interventional Science, University College London, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses the importance of a multidisciplinary approach to the treatment of patients with localized prostate cancer.

Mark G. Kris, MD, FASCO

Latest:

Current Treatment Options for Patients with NSCLC

Mark G. Kris, MD, FASCO shares an overview of existing treatment options for patients with stage I-III non-small cell lung cancer.

Mark G. Kris, MD, Memorial Sloan-Kettering Cancer Center

Mark G. Kris, MD, MSKCC

Mark H. O'Hara, MD

Latest:

Dr. O'Hara on the Rationale for APX005M in Combination With Chemotherapy and Nivolumab in Pancreatic Cancer

Mark H. O’Hara, MD, assistant professor of medicine, Hospital of the University of Pennsylvania, discusses the rationale for evaluating APX005M in combination with chemotherapy and nivolumab (Opdivo) in pancreatic cancer.

Mark H. OHara, MD, Hospital of the University of Pennsylvania

Mark Heaney, MD, PhD

Mark J. Levis, MD, PhD, Johns Hopkins University

Latest:

Combining and Sequencing FLT3 Inhibitors in AML

Harry Erba, MD, PhD; Courtney DiNardo, MD; Mark Levis, MD, PhD; and Vinod Pullarkat, MD, review factors to consider when using combining and/or sequencing first- or second-generation FLT3 inhibitors for patients with acute myeloid leukemia (AML).

Mark J. Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center

Mark J. Mann, MD

Latest:

Dr. Mann on Differences Between Treatments for Prostate Cancer

Mark J. Mann, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the differences between treatment options for patients with prostate cancer subtypes.

Mark J. Roschewski, MD

Latest:

Dr. Roschewski on the Use of DA-EPOCH-R in Burkitt Lymphoma

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the use of dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan; DA-EPOCH-R) in patients with Burkitt lymphoma.

Mark J. Truty, MD, MS

Latest:

Dr. Truty on Challenges With Treating Patients With Pancreatic Cancer

Mark J. Truty, MD, MS, assistant professor of surgery, Mayo Clinic, discusses challenges with treating patients with pancreatic cancer.

Mark James Levis, MD, PhD

Latest:

Dr Levis on Maintenance Gilteritinib After ASCT in FLT3-ITD+ AML

Mark J. Levis, MD, PhD, discusses data from the phase 3 BMT CTN 1506/MORPHO trial of gilteritinib as maintenance therapy following allogeneic stem cell transplant in patients With FLT3-ITD–positive acute myeloid leukemia.

Mark Kozloff, MD, Ingalls Cancer Care

Mark Kris, MD, Memorial Sloan-Kettering

Mark Kris, MD, Memorial Sloan Kettering Cancer Center